Reaction
Retinal Disorder reporting signals
As of the last recalculation, Retinal Disorder appears in 2,572 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 48.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 149 | 48.2 | 48.4 |
| Vigabatrin | 58 | 32.9 | 33.0 |
| Aflibercept | 72 | 19.2 | 19.2 |
| Quinine | 17 | 16.1 | 16.2 |
| Faricimab | 16 | 16.1 | 16.1 |
| Travoprost | 17 | 16.0 | 16.0 |
| Timolol | 19 | 12.8 | 12.8 |
| Dorzolamide Hydrochloride And Timolol Maleate | 10 | 10.3 | 10.3 |
| Insulin Human | 45 | 9.3 | 9.3 |
| Brimonidine Tartrate | 19 | 8.7 | 8.7 |
| Prednisolone Acetate | 10 | 7.8 | 7.9 |
| Cefuroxime | 11 | 7.8 | 7.8 |
| Brinzolamide | 8 | 7.5 | 7.5 |
| Encorafenib | 9 | 7.4 | 7.4 |
| Timolol Maleate | 8 | 6.6 | 6.6 |
| Insulin Lispro | 107 | 6.5 | 6.5 |
| Latanoprost | 38 | 6.2 | 6.2 |
| Ganciclovir Sodium | 8 | 6.1 | 6.1 |
| Carboxymethylcellulose Sodium | 7 | 6.0 | 6.0 |
| Nebivolol | 11 | 5.6 | 5.6 |
| Dabrafenib | 14 | 5.4 | 5.4 |
| Trametinib | 16 | 5.4 | 5.4 |
| Bevacizumab | 74 | 4.9 | 5.0 |
| Fingolimod Hcl | 52 | 4.9 | 4.9 |
| Rifampicin | 6 | 4.8 | 4.8 |
| Tobramycin Sulfate | 7 | 4.6 | 4.6 |
| Insulin Glargine | 129 | 4.4 | 4.4 |
| Bimatoprost | 14 | 3.9 | 3.9 |
| Peginterferon Alfa-2A | 20 | 3.0 | 3.0 |
| Ravulizumab | 5 | 3.0 | 3.0 |
| Lifitegrast | 5 | 2.5 | 2.5 |
| Pseudoephedrine Hydrochloride | 3 | 2.4 | 2.4 |
| Exenatide | 15 | 2.3 | 2.3 |
| Pseudoephedrine Hcl | 3 | 2.2 | 2.2 |
| Cenegermin-Bkbj | 3 | 2.0 | 2.0 |